Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

Dermal IgA deposition without symptoms is rare in Dermatitis herpetiformis risk groups.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

This study found that conditional expression of TGFβ1 in mice affects epidermal and hair follicle growth, with chronic expression causing severe alopecia and a negative feedback loop involving Smad7.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

In this retrospective case series, therapeutic responses to immunomodulatory and incretin-based therapies for Dercum's disease showed considerable individual variation, suggesting these treatments might be exploratory options when surgery isn't feasible, though further controlled studies are needed for definitive conclusions.

This case report describes a 29-year-old woman diagnosed with both systemic lupus erythematosus and Graves' disease, illustrating the occurrence of autoimmune polyendocrine syndromes with specific combinations of autoimmune disorders.

This review discusses the skin conditions associated with endocrine diseases in children and adolescents, emphasizing their importance in early diagnosis and treatment, but presents no new clinical findings.

This study found that a single application of TCDD on the skin of hairless mice altered epidermal differentiation, changing keratin expression patterns similarly to a known tumor promoter.

This study observed that, among women of reproductive age with prediabetes, those treated with a combination of metformin and liraglutide experienced greater weight loss, a more significant decrease in visceral adiposity index, and higher rates of HbA1C normalization compared to those receiving metformin and inositol.

This case series reports three cats diagnosed with hypersomatotropism due to GH-secreting pituitary adenomas without concurrent diabetes mellitus, highlighting the potential for underdiagnosis in non-diabetic cats.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.

This study reported successful treatment of biotin deficiency in three patients receiving total parenteral nutrition, suggesting current biotin supplementation recommendations may be inadequate to maintain normal biotin status.

This case report describes a girl in China with biotinidase deficiency confirmed by genetic mutations, whose skin and hair symptoms improved with biotin therapy.

This study concluded that 2-hour oral glucose tolerance tests are crucial for screening glycemic disorders in women with PCOS, as HbA1c was found to be an unsatisfactory tool for predicting glycemic disorders within this group.

This review highlights the eye and skin manifestations of endocrine-related metabolic diseases but provides no new clinical results.

In this study, patients with diabetic retinopathy and peripheral occlusive arterial disease had significantly longer diabetes duration, higher HbA1c levels, poorer glycemic control, and were more often smokers compared to those without arterial disease, suggesting these factors contribute to disease development.

This review discusses dermocosmetic care for managing DM-related dermatoses, reporting improved skin conditions and quality of life in patients, but highlights limited clinical evidence for these products.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This report describes a 38-year-old female diagnosed with autoimmune polyendocrine syndrome Type II after presenting with shock.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This case study reports that carbimazole therapy led to significant hair regrowth and a drop in thyrotropin receptor antibody levels in an 11-year-old girl diagnosed with alopecia areata and Graves' disease.

This case report describes trichothiodystrophy in two sisters with only hair fragility, illustrating the condition's variable presentation and the importance of regular monitoring for potential associated impairments.

This review discusses the epidemiology, clinical manifestations, and pathogenesis of autoimmune skin diseases and their associations with thyroid diseases, reporting no new clinical results.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.